Vertex Pharmaceuticals Inc. revealed that a combination including one of its experimental cystic fibrosis drugs failed to show a significant benefit in one of the most challenging CF subpopulations, but three other Phase III trials of the combo are ongoing with an FDA filing anticipated in late 2017.
The company will terminate the study testing the combination of the firm's first marketed CF drug, Kalydeco (ivacaftor), and the...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)